• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

FDA approves Bracco’s LumenHance

Article

Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has

Contrast agent developer Bracco Diagnostics of Princeton, NJ, in December received Food and Drug Administration approval for its LumenHance (manganese chloride tetrahydrate) oral contrast agent for enhancing gastrointestinal MRI studies. Bracco has licensed the agent from its developer, ImaRx Pharmaceutical of Tucson.

Recent Videos
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Related Content
© 2025 MJH Life Sciences

All rights reserved.